drugset / Trial / NCT00913120

Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery

NCT00913120

Phase 2/3 Completed 610 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total hip replacement surgery.

Timeline

Start
2009-05
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enoxaparin sodium Other / unclassified Other
Subject darexaban Small molecule Oral